Penumbra, Inc. (NYSE:PEN) Shares Sold by Man Group plc

Man Group plc decreased its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 85.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,396 shares of the company's stock after selling 124,589 shares during the quarter. Man Group plc owned about 0.05% of Penumbra worth $4,844,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PEN. Barclays PLC increased its stake in Penumbra by 16.5% during the third quarter. Barclays PLC now owns 18,025 shares of the company's stock worth $3,502,000 after acquiring an additional 2,559 shares during the last quarter. Park Avenue Securities LLC grew its stake in shares of Penumbra by 18.6% in the fourth quarter. Park Avenue Securities LLC now owns 1,665 shares of the company's stock valued at $395,000 after buying an additional 261 shares in the last quarter. Diversify Wealth Management LLC grew its stake in shares of Penumbra by 36.3% in the fourth quarter. Diversify Wealth Management LLC now owns 1,645 shares of the company's stock valued at $412,000 after buying an additional 438 shares in the last quarter. UMB Bank n.a. boosted its holdings in Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after purchasing an additional 70 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Penumbra by 43.4% in the fourth quarter. Blue Trust Inc. now owns 730 shares of the company's stock valued at $173,000 after purchasing an additional 221 shares during the period. Institutional investors and hedge funds own 88.88% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PEN. Truist Financial lifted their target price on Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a report on Thursday, April 24th. UBS Group reiterated a "buy" rating and issued a $330.00 target price (up from $320.00) on shares of Penumbra in a report on Thursday, April 24th. Stifel Nicolaus set a $318.00 target price on Penumbra and gave the company a "buy" rating in a report on Thursday, April 24th. JPMorgan Chase & Co. lifted their target price on Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Finally, Robert W. Baird lifted their target price on Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $302.40.

Penumbra Stock Performance

Shares of Penumbra stock traded up $1.97 on Friday, hitting $268.72. The stock had a trading volume of 235,921 shares, compared to its average volume of 443,992. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The stock has a market cap of $10.41 billion, a price-to-earnings ratio of 790.35, a P/E/G ratio of 2.83 and a beta of 0.53. The company's 50 day moving average price is $279.68 and its 200 day moving average price is $265.17.

Penumbra (NYSE:PEN - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The business had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. During the same period in the previous year, the business earned $0.41 EPS. The business's quarterly revenue was up 16.3% on a year-over-year basis. On average, research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Activity at Penumbra

In other Penumbra news, CFO Maggie Yuen sold 2,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $286.00, for a total transaction of $572,000.00. Following the transaction, the chief financial officer now owns 15,243 shares in the company, valued at approximately $4,359,498. The trade was a 11.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total value of $172,458.00. Following the transaction, the executive vice president now owns 66,539 shares in the company, valued at $19,125,304.77. The trade was a 0.89% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 176,696 shares of company stock worth $50,207,745 in the last quarter. Company insiders own 4.20% of the company's stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.